37 related articles for article (PubMed ID: 3655404)
1. A recombinant rabies virus encoding two copies of the glycoprotein gene confers protection in dogs against a virulent challenge.
Liu X; Yang Y; Sun Z; Chen J; Ai J; Dun C; Fu ZF; Niu X; Guo X
PLoS One; 2014; 9(2):e87105. PubMed ID: 24498294
[TBL] [Abstract][Full Text] [Related]
2. Protective vaccine-induced CD4(+) T cell-independent B cell responses against rabies infection.
Dorfmeier CL; Lytle AG; Dunkel AL; Gatt A; McGettigan JP
J Virol; 2012 Nov; 86(21):11533-40. PubMed ID: 22896601
[TBL] [Abstract][Full Text] [Related]
3. Cross-protective and cross-reactive immune responses to recombinant vaccinia viruses expressing full-length lyssavirus glycoprotein genes.
Weyer J; Kuzmin IV; Rupprecht CE; Nel LH
Epidemiol Infect; 2008 May; 136(5):670-8. PubMed ID: 17588277
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of cytochrome C by a recombinant rabies virus attenuates pathogenicity and enhances antiviral immunity.
Pulmanausahakul R; Faber M; Morimoto K; Spitsin S; Weihe E; Hooper DC; Schnell MJ; Dietzschold B
J Virol; 2001 Nov; 75(22):10800-7. PubMed ID: 11602721
[TBL] [Abstract][Full Text] [Related]
5. Unmodified rabies mRNA vaccine elicits high cross-neutralizing antibody titers and diverse B cell memory responses.
Hellgren F; Cagigi A; Arcoverde Cerveira R; Ols S; Kern T; Lin A; Eriksson B; Dodds MG; Jasny E; Schwendt K; Freuling C; Müller T; Corcoran M; Karlsson Hedestam GB; Petsch B; Loré K
Nat Commun; 2023 Jun; 14(1):3713. PubMed ID: 37349310
[TBL] [Abstract][Full Text] [Related]
6. Potency, immunogenicity, and efficacy of rabies vaccine: In vitro and in vivo approach.
Akter F; Shamimuzzaman M
Immun Inflamm Dis; 2024 Feb; 12(2):e1198. PubMed ID: 38411335
[TBL] [Abstract][Full Text] [Related]
7. Protection Against CNS-Targeted Rabies Virus Infection is Dependent upon Type-1 Immune Mechanisms Induced by Live-Attenuated Rabies Vaccines.
Lebrun A; Garcia S; Li J; Kean RB; Hooper DC
Trop Med Infect Dis; 2017 Jul; 2(3):. PubMed ID: 30270881
[TBL] [Abstract][Full Text] [Related]
8. Recombinant rabies virus with the glycoprotein fused with a DC-binding peptide is an efficacious rabies vaccine.
Zhang Y; Zhou M; Li Y; Luo Z; Chen H; Cui M; Fu ZF; Zhao L
Oncotarget; 2018 Jan; 9(1):831-841. PubMed ID: 29416659
[TBL] [Abstract][Full Text] [Related]
9. Author Correction: Unmodified rabies mRNA vaccine elicits high cross-neutralizing antibody titers and diverse B cell memory responses.
Hellgren F; Cagigi A; Arcoverde Cerveira R; Ols S; Kern T; Lin A; Eriksson B; Dodds MG; Jasny E; Schwendt K; Freuling C; Müller T; Corcoran M; Karlsson Hedestam GB; Petsch B; Loré K
Nat Commun; 2023 Jul; 14(1):4080. PubMed ID: 37429868
[No Abstract] [Full Text] [Related]
10. A new rabies vaccine based on a recombinant ORF virus (parapoxvirus) expressing the rabies virus glycoprotein.
Amann R; Rohde J; Wulle U; Conlee D; Raue R; Martinon O; Rziha HJ
J Virol; 2013 Feb; 87(3):1618-30. PubMed ID: 23175365
[TBL] [Abstract][Full Text] [Related]
11. Expression of the rabies virus nucleoprotein in plants at high-levels and evaluation of immune responses in mice.
Perea Arango I; Loza Rubio E; Rojas Anaya E; Olivera Flores T; Gonzalez de la Vara L; Gómez Lim MA
Plant Cell Rep; 2008 Apr; 27(4):677-85. PubMed ID: 18270708
[TBL] [Abstract][Full Text] [Related]
12. The glycoprotein G of rhabdoviruses.
Coll JM
Arch Virol; 1995; 140(5):827-51. PubMed ID: 7605197
[TBL] [Abstract][Full Text] [Related]
13. Interleukin 2 acts as an adjuvant to increase the potency of inactivated rabies virus vaccine.
Nunberg JH; Doyle MV; York SM; York CJ
Proc Natl Acad Sci U S A; 1989 Jun; 86(11):4240-3. PubMed ID: 2786210
[TBL] [Abstract][Full Text] [Related]
14. T and B cell human responses to European bat lyssavirus after post-exposure rabies vaccination.
Herzog M; Fritzell C; Lafage M; Montaño Hirose JA; Scott-Algara D; Lafon M
Clin Exp Immunol; 1991 Aug; 85(2):224-30. PubMed ID: 1864001
[TBL] [Abstract][Full Text] [Related]
15. Cells with natural killer activity in human rabies.
Panpanich T; Hemachudha T; Piyasirisilp S; Manatsathit S; Wilde H; Phanuphak P
Clin Exp Immunol; 1992 Sep; 89(3):414-8. PubMed ID: 1381301
[TBL] [Abstract][Full Text] [Related]
16. Antigenic variation in rabies and rabies-related viruses: cross-protection independent of glycoprotein-mediated virus-neutralizing antibody.
Dietzschold B; Tollis M; Rupprecht CE; Celis E; Koprowski H
J Infect Dis; 1987 Nov; 156(5):815-22. PubMed ID: 3655404
[TBL] [Abstract][Full Text] [Related]
17. Immunity against the European bat rabies (Duvenhage) virus induced by rabies vaccines: an experimental study in mice.
Lafon M; Bourhy H; Sureau P
Vaccine; 1988 Aug; 6(4):362-8. PubMed ID: 2461007
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a new virus-neutralizing epitope that denotes a sequential determinant on the rabies virus glycoprotein.
Bunschoten H; Gore M; Claassen IJ; Uytdehaag FG; Dietzschold B; Wunner WH; Osterhaus AD
J Gen Virol; 1989 Feb; 70 ( Pt 2)():291-8. PubMed ID: 2471786
[TBL] [Abstract][Full Text] [Related]
19. Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene.
Wiktor TJ; Macfarlan RI; Reagan KJ; Dietzschold B; Curtis PJ; Wunner WH; Kieny MP; Lathe R; Lecocq JP; Mackett M
Proc Natl Acad Sci U S A; 1984 Nov; 81(22):7194-8. PubMed ID: 6095272
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
